FDA Still Needs Convincing On Use Of Non-Inferiority Trials For CAP – Temple
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Industry has provided little data supporting the use of non-inferiority trials as the basis for approval for community-acquired pneumonia, FDA Office of Medical Policy Director Bob Temple said at a recent workshop on clinical trial design for CAP